The Union Budget: Health Delivery to the Poor
What has the new Union Budget done for health? A
stronger focus on rural health, insurance for people below the poverty
line, and cheaper heart devices. In the next three months, the Health
Ministry aims to identify difficult, most difficult and inaccessible areas
particularly in hilly states and tribal areas. All efforts will be made to
fill up vacancies of health personnel in these areas. The government is
planning to start financial incentives for doctors to work in rural areas.
Salaries will be nearly double of that earned in urban areas. Contractual
appointments are also being planned. By the end of July 2009, the
government also plans to have a fully functional web based health
management information system (HMIS) to monitor the progress and status of
the National Rural Health Mission.
To correct the regional imbalance in the availability
of affordable and reliable healthcare services, 6 AIIMS like institutions
are being established in Patna, Raipur, Bhopal, Bhubaneswar, Jodhpur and
Rishikesh. The Government has also made a commitment to revive the three
vaccine manufacturing units in Kasauli, Guindy and Coonoor.
6.5 crore families living below poverty level will be
covered under the Rajya Swasthya Bima Yojna. Already 46 lakh such families
have been issued biometric smart cards, which enable them to access health
care from a list of public and private hospitals.
The union budget has also allocated Rs 10 crore for the
National Program for Prevention and Control of Deafness (NPPCD). It aims
to prevent avoidable hearing loss and ensure early identification,
diagnosis and treatment of ear problems responsible for hearing loss and
deafness. Planning the health of a billion people is a challenge worthy of
great visionaries. (The Hindu, 2 July 2009).
Bioprospecting: Searching for New Drugs
In the 19th century, a pharmacist’s apprentice
discovered morphine in the latex resin of the opium poppy plant. Even
today it remains one of the most widely used painkillers. Since then
nature has yielded many secrets to combat various illnesses – from
penicillin to aspirin and digoxin. About 50% of all pharmaceuticals in use
today are derived from natural sources. So, scientists tirelessly screen
thousands of plants for medicinal value. But such bioprospecting can be
laborious with hardly 1 useful product for every 20,000 screened.
To improve yields many techniques have been used.
Consulting the indigenous people has enhanced success by 60%. Other good
sources for drugs are toxins from sessile or slow moving marine
invertebrates like sponges, sea slugs and corals.
Identifying the molecule is only the first step. Next
comes developing renewable resources for accessing large quantities of the
chemical. Then come the phase I, II and III trials. Ethical dilemmas about
intellectual property rights abound. And the worst problem is that the
very sources of these natural drugs are slowly disappearing.
The result is that big pharmaceutical companies are now
systematically shifting away from screening natural products to synthetic
ones. There has been a decline of upto 30% in the number of natural drugs
screened. They use a rapid technique called high throughput screening
which allows them to test 100,000 synthetic molecules per day. The
interesting point is that though screening synthetic molecules are easier
and much faster, the number that finally get drug status approval are
still lower than those from natural resources. With millions of years of
experience behind her, nature is hard to beat. (Scientific American 9
July 2009)